Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01994174
Recruitment Status : Recruiting
First Posted : November 25, 2013
Last Update Posted : June 5, 2020
Sponsor:
Information provided by (Responsible Party):
Vikas Gulati, MD, University of Nebraska

Brief Summary:
The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly injection of anti VEGF agents.

Condition or disease
Macular Disease

Detailed Description:

Intravitreal injection of different anti-VEGF agents such as bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA, USA) ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA) and aflibercept (Eylea, Regeneron, Tarrytown, NY, USA) has been a widely common practice for treatment of choroidal neovascularization and retinal vascular diseases [1]. Several ocular and systemic adverse events have been reported with the use of anti-VEGF agents [7]. Elevation of intraocular pressure (IOP) is a serious ocular adverse event that may be associated with intravitreal injection of anti-VEGF agents. IOP elevation with anti-VEGF injection may have variable presentation ranging from acute transient post injection elevation to the development of persistent IOP elevation that mandates pressure lowering therapy[8].

Patients with previously existing glaucoma may have a higher rate of persistent IOP elevation associated with intravitreal injection of anti-VEGF agents. Good et al, reported the rate of persistent IOP elevation after intravitreal anti-VEGF to be 33% in glaucoma patients versus 3.1% in eyes without previous diagnosis of glaucoma [9]. Tseng et al, reported 25 eyes with sustained elevation of IOP after serial intravitreal injections of anti-VEGF agents (mean = 20injections). All the 25 eyes were normotensive prior to the study and 23 of them were not previously diagnosed with glaucoma[10].

Multicenter clinical trials that studied the intravitreal injection of anti-VEGF agents, such as MARINA and ANCHOR for ranibizumab, VISION for pegaptanib and PACORES for bevacizumab, did not show sustained IOP elevation with the intravitreal injection of the study agents [12-15]. However, a subgroup analysis of the data of MARINA and ANCHOR trials showed at least 6 mm Hg increase of IOP from baseline in 2.1% of eyes in MARINA trial and 3.6% of eyes in ANCHOR trial [16]. A retrospective chart review of 207 patients over a 6-months follow up period after serial intravitreal injections of anti-VEGF reported an IOP elevation greater than 5 mm Hg in 2 consecutive visits compared to baseline in 11.6% of the treated eyes versus 5.3% in control eyes [17].

The pathophysiology of the reported IOP elevation associated with intravitreal injection of anti-VEGF is unknown. Anti-VEGF compounds might increase aqueous humor inflow by the breakdown of the blood-aqueous barrier or reduce uveoscleral outflow by the ciliary body vasculature. These potential changes could translate into elevated IOP and glaucoma.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 4 Weeks
Official Title: Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
Actual Study Start Date : February 2014
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2021



Primary Outcome Measures :
  1. Uveoscleral outflow changes [ Time Frame: 1-2 months ]
    The uveoscleral outflow changes will be assess at baseline prior to any anti-VEGF treatment and after the 3rd intravitreal treatment has been done.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with established diagnosis of retinal vascular diseases (diabetic macular edema, neovascular macular degeneration, presumed ocular histoplasmosis syndrome, high myopia) who require intravitreal injection of anti-VEGF drugs such as bevacizumab, ranibizumab or aflibercept and are likely to need three monthly doses.
Criteria

Inclusion Criteria:

  • Subjects must be at least 19 years of age and older
  • Ability to give informed consent and attend the study visits
  • Patients with established diagnosis of retinal vascular diseases (diabetic macular edema, neovascular macular degeneration,presumed ocular histoplasmosis syndrome, high myopia) who require intravitreal injection of anti-VEGF drugs such as bevacizumab,ranibizumab or aflibercept and are likely to need three monthly doses.
  • Patients who have not received intravitreal injections within 3 months of study entry
  • No previous established diagnosis of glaucoma and consequently no previous history of Argon Laser Trabeculoplasty (ALT) or Selective Laser Trabeculoplasty (SLT).
  • No previous history of ocular surgery
  • Patients who are not planning on and are unlikely to require an elective ocular surgical or laser procedure within the study duration
  • Open angle of the anterior chamber on clinical examination
  • Ability to cooperate for aqueous humor dynamic studies
  • Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session
  • Able to participate on site over the multi-visit study period

Exclusion Criteria:

  • Age less than 18 years of age
  • Women who are pregnant or nursing
  • Ocular hypertension or glaucoma
  • Narrow angle with complete or partial closure (gonioscopy angle <2)
  • Any previous surgical or laser procedures
  • Secondary glaucoma including pigmentary, exfoliative, uveitic and traumatic glaucomas
  • Any active neovascularization of the iris, angle, disc or retina
  • Diagnosis of retinal arterial or vein occlusion
  • Chronic or recurrent inflammatory eye disease
  • Ocular trauma within the past 6 months
  • Ocular infection or ocular inflammation in the past 2 months
  • Any abnormality preventing reliable fluorophotometry of either eye,such as corneal scarring or severe dry eye that results in punctuate fluorescein staining of the cornea
  • Intraocular surgery within 6 months
  • Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.
  • Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01994174


Contacts
Layout table for location contacts
Contact: Vikas Gulati, MD 402-559-4276 vgulati@unmc.edu
Contact: Kristi Miller 402-559-1853 kristi.miller@unmc.edu

Locations
Layout table for location information
United States, Nebraska
University of Nebraska Medical Center, Truhlsen Eye Institute Recruiting
Omaha, Nebraska, United States, 68105
Contact: Vikas Gulati, MD    402-559-4276    vgulati@unmc.edu   
Contact: Kristi Miller    402-559-1853    Kristi.miller@unmc.edu   
Sub-Investigator: Shane Havens, MD         
Sub-Investigator: Kunal Dansingani, MD         
Sub-Investigator: Carol B Toris, PhD         
University of Nebraska Medical Center, Department of Ophthalmology and Visual Sciences Recruiting
Omaha, Nebraska, United States, 68198-5540
Contact: Vikas Gulati, MD    402-559-4276    vgulati@unmc.edu   
Contact: Kristi Miller    402-559-1853    kristi.miller@unmc.edu   
Principal Investigator: Vikas Gulati, MD         
Sponsors and Collaborators
University of Nebraska
Investigators
Layout table for investigator information
Principal Investigator: Vikas Gulati, MD UNMC Department of Ophthalmology and Visual Sciences
Additional Information:

Layout table for additonal information
Responsible Party: Vikas Gulati, MD, Associate Professor, University of Nebraska
ClinicalTrials.gov Identifier: NCT01994174    
Other Study ID Numbers: 583-13-FB
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: June 5, 2020
Last Verified: June 2020
Keywords provided by Vikas Gulati, MD, University of Nebraska:
vascular
retina
Anti-VEGF
Aqueous humor dynamics